ReNeuron Group plc
RENE.L · LSE
3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| FCF Yield | -14,901.64% | -4,438.48% | -1,305.10% | -4,579.68% |
| EV / EBITDA | 0.89 | 0.82 | 1.04 | 0.85 |
| Quality | ||||
| ROIC | -105.51% | -94.14% | -55.68% | -84.18% |
| Gross Margin | 49.62% | 19.60% | -3,597.67% | -169.33% |
| Cash Conversion Ratio | 1.12 | 0.67 | 0.45 | 1.03 |
| Growth | ||||
| Revenue 3-Year CAGR | 27.29% | -59.50% | 73.75% | 420.54% |
| Free Cash Flow Growth | 0.12% | -26.92% | 57.87% | -18.42% |
| Safety | ||||
| Net Debt / EBITDA | 0.90 | 0.84 | 1.08 | 0.88 |
| Interest Coverage | -355.75 | -449.12 | -403.56 | -343.07 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -91.75 | -341.42 | 600.32 | -12.32 |